RIGI and neoplasm: we intraperitoneally administered 250 μg control immunoglobulin (cIg) or neutralising antibodies against CD8a (anti-CD8a) to both Rig-I+/+ and Rig-I−/− mice before and after subcutaneous inoculation with MC38 tumours to further investigate the role of CD8+ T cells in the enhanced anti-tumour immunity of Rig-I knockout mice, and the results revealed that Rig-I−/− CD8+ T cells play a crucial role in the anti-tumour function (Fig. 3D).